Please assess the completion status of the following clinical trial:

Trial Title: PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women on adequate contraception if they are of child-bearing age.~* Meet revised ACR criteria for RA.~* Stable doses of DMARDS,biologic agents and or corticosteroids for at least 3 months.~Exclusion Criteria:~* Pregnant or lactating women.~* Current smokers or individuals who smoked in the last 6 months.~* Diagnosis of Diabetes, heart failure, or infection.~* Current diagnosis of malignant disease except for basal cell or squamous cell carcinoma of the skin.~* No active liver disease.~* No cholesterol-lowering medications or oral hypoglycemic agents.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone then placebo (Type: OTHER): Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
- placebo then study drug (pioglitazone) (Type: OTHER): Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.

Based on this trial design, predict the completion outcome and termination type (if applicable).